

In the Claims

Please cancel claims 1-36 and add new claims 37-51, as follows:

Claims 1-36 (canceled)

37. (new) A method of activating lymphocytes in a subject, comprising administering to a subject an oligonucleotide delivery complex, wherein the oligonucleotide delivery complex comprises
- an immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence, wherein the CpG dinucleotide sequence is not part of a palindromic sequence, and
 - an agent associated with the immunostimulatory oligonucleotide, wherein the agent is chosen from a sterol, a lipid, a virosome, a liposome, and a target cell-specific binding agent, in an effective amount to activate lymphocytes in the subject.
38. (new) The method of claim 37, wherein the immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence comprises a plurality of CpG dinucleotide sequences.
39. (new) The method of claim 37, wherein the immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence comprises a plurality of CpG dinucleotide sequences, wherein at least one CpG dinucleotide sequence is part of a palindromic sequence and wherein at least one CpG dinucleotide sequence is not part of a palindromic sequence.
40. (new) A method of activating lymphocytes in a subject, comprising administering to a subject having an immune system deficiency an oligonucleotide delivery complex, wherein the oligonucleotide delivery complex comprises
- an immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence, and
 - an agent associated with the immunostimulatory oligonucleotide, wherein the agent is chosen from a sterol and a target cell-specific binding agent, in an effective amount to activate lymphocytes in the subject.

41. (new) A method of treating an immune system deficiency in a subject, comprising administering to a subject having an immune system deficiency an oligonucleotide delivery complex, wherein the oligonucleotide delivery complex comprises an immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence, wherein the CpG dinucleotide sequence is not part of a palindromic sequence, and an agent associated with the immunostimulatory oligonucleotide, wherein the agent is chosen from a sterol, a lipid, a virosome, a liposome, and a target cell-specific binding agent, in an effective amount to treat the immune system deficiency in the subject.
42. (new) The method of claim 41, wherein the immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence comprises a plurality of CpG dinucleotide sequences.
43. (new) The method of claim 41, wherein the immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence comprises a plurality of CpG dinucleotide sequences, wherein at least one CpG dinucleotide sequence is part of a palindromic sequence and wherein at least one CpG dinucleotide sequence is not part of a palindromic sequence.
44. (new) A method of treating an immune system deficiency in a subject, comprising administering to a subject having an immune system deficiency an oligonucleotide delivery complex, wherein the oligonucleotide delivery complex comprises an immunostimulatory oligonucleotide comprising a CpG dinucleotide sequence, and an agent associated with the immunostimulatory oligonucleotide, wherein the agent is chosen from a sterol and a target cell-specific binding agent, in an effective amount to treat the immune system deficiency in the subject.
45. (new) The method of any one of claims 37-44, wherein the immunostimulatory oligonucleotide is a stabilized oligonucleotide.
46. (new) The method of any one of claims 37-44, wherein the immunostimulatory oligonucleotide is a phosphorothioate stabilized oligonucleotide.

47. (new) The method of any one of claims 37-44, wherein the sterol is cholesterol.
48. (new) The method of one of claims 37 or 41, wherein the lipid is a cationic lipid.
49. (new) The method of any one of claims 37-44, wherein the target cell-specific binding agent is a ligand recognized by a target cell-specific receptor.
50. (new) The method of any one of claims 37-44, wherein the immunostimulatory oligonucleotide and the agent are covalently associated.
51. (new) The method of any one of claims 37-44, wherein the immunostimulatory oligonucleotide is 8-40 nucleotides long.